Applied Biology, Inc. (“Applied Biology”) announced today it has licensed to Applied Botanics, LLC. (Louisville, KY) intellectual property rights to a novel cannabinoid based therapy under development for COVID-19 and other respiratory illnesses.
IRVINE, Calif., April 13, 2020 /PRNewswire/ -- Applied Biology, Inc. (“Applied Biology”) announced today it has licensed to Applied Botanics, LLC. (Louisville, KY) intellectual property rights to a novel cannabinoid based therapy under development for COVID-19 and other respiratory illnesses. Applied Biology, Inc. is a biotechnology innovator focused on the development of treatments and diagnostics for androgen mediated diseases. Recently, Applied Biology’s scientific team in collaboration with researchers around the world made a breakthrough discovery that the difference in mortality rate among men and women COVID-19 patients may be due to androgen levels. This discovery was recently published in two peer-reviewed medical journals (https://doi.org/10.1111/dth.13365). On the heels of this discovery, Applied Biology has commenced the development program for anti-androgen therapy as a prophylactic for COVID-19 infection. According to Applied Biology’s Chief Medical Officer, Dr. Andy Goren: “provided our discovery proves correct in larger studies, anti-androgens may prove as an effective treatment for COVID-19 and other respiratory illnesses. Interestingly, research suggests that cannabinoid may act as an anti-androgen; thus, exploring the development of a cannabinoid based drug therapy for COVID-19 is of great interest.” Kawel LauBach, Applied Botanics Chief Executive Officer states: “we are passionate about the evolving field of cannabinoids (CBD) research and are excited to be working with Dr. Goren and this distinguished team of scientists on such a monumental and potentially impactful project.” The company plans to release additional information as it advances its drug development program. ABOUT APPLIED BOTANICS ABOUT APPLIED BIOLOGY CONTACT View original content:http://www.prnewswire.com/news-releases/applied-biology-to-license-intellectual-property-rights-to-a-novel-cannabinoid-based-therapy-under-development-for-covid-19-301039657.html SOURCE Applied Biology, Inc. |